T
TransCode Therapeutics, Inc. (RNAZ)
NCM – Real vaqt narxi. Valyuta: USD
4.97
+0.42 (9.23%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.83
-0.14 (-2.82%)
Bozordan keyin: Jun 26, 2026, 6:14 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
4.97
+0.42 (9.23%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
4.83
-0.14 (-2.82%)
Bozordan keyin: Jun 26, 2026, 6:14 PM EDT
TransCode Therapeutics, Inc., klinik bosqichdagi kompaniya bo'lib, yuqori xavfli va rivojlangan saratonni davolash uchun immuno-onkologiya va RNK terapiyasini ishlab chiqadi. Kompaniyaning terapevtik nomzodi 2-bosqich klinik sinovdan o'tgan IIB va IIC melanomali bemorlarni qo'shimcha davolash uchun SEVIPROTIMUT-L ni o'z ichiga oladi; TTX-MC138, metastatik hujayra hayotiyligining asosiy regulyatori bo'lgan mikroRNA-10b ni nishonga oladi, bu ko'krak, oshqozon osti bezi, tuxumdon, yo'g'on ichak saratoni, glialoblastomalar va boshqalar kabi turli xil saraton kasalliklarini o'z ichiga oladi, bu 1-bosqich klinik sinovdan o'tgan. Uning preklinik dasturlari TTX-siPDL1, dasturlashtirilgan o'lim ligandini 1 modulyatorini va ikkita ko'rsatkichdan qat'i nazar dasturlarni o'z ichiga oladi; TTX-RIGA, o'simta mikro-muhitida tug'ma immunitetni faollashtirishga qaratilgan retinoik kislota bilan indüklangan gen I ning RNK asosidagi agonisti; va TTX-siMYC, siRNA asosidagi MYC ingibitori. Kompaniya shuningdek, onkolitik virus terapiyasini ishlab chiqmoqda. TransCode Therapeutics, Inc. Texas universiteti M. D. Anderson saraton markazi bilan strategik hamkorlik shartnomasiga ega. Kompaniya 2016-yilda tashkil etilgan va Boston, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Anna Moore Ph.D. | Scientific Co-Founder, Scientific Advisor & Chair of Scientific Advisory Board |
| Dr. Daniel R. Vlock M.D. | Chief Medical Officer |
| Dr. Michel Janicot PH.D. | Consulting Head of Translational Science |
| Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. | CEO & Executive Chairman of the Board |
| Dr. Zdravka Medarova Ph.D. | Scientific Co-Founder & Chief Scientific Officer |
| Mr. Thomas A. Fitzgerald M.B.A. | CFO, President, VP of Administration & Director |
| Ms. Susan Duggan M.B.A., R.N. | Senior Vice President of Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-18 | 8-K | tm2618153d1_8k.htm |
| 2026-06-03 | 8-K | tm2616719d1_8k.htm |
| 2026-06-02 | DEF 14A | tm2613174-4_def14a.htm |
| 2026-06-02 | ARS | tm2616320d1_ars.pdf |
| 2026-06-01 | 8-K | tm2616319d1_8k.htm |
| 2026-05-26 | DEFA14A | tm2615597d1_8ka.htm |
| 2026-05-26 | 8-K/A | tm2615597d1_8ka.htm |
| 2026-05-22 | 8-K | tm2615385d1_8k.htm |
| 2026-05-15 | 10-Q | rnaz-20260331x10q.htm |
| 2026-05-08 | PRE 14A | tm2613174-1_pre14a.htm |